CX3CR1 and non-small cell lung carcinoma: The same study observed a higher frequency of the CX3CR1+ subset on circulating CD8+ T cells shortly after treatment initiation in patients with non-small-cell lung cancer (NSCLC) treated with anti-PD-1.